Biotechnology major Biocon which today posted a strong first quarter earnings raised concerns about confusion in the India drug pricing policy which has impacted the growth of the pharma-biotech sector.

Biocon Q1: Analysts expect net to rise 6% at Rs 83.8 cr

Biocon's revenues are expected to go up by 15% to Rs 664 crore in April-June quarter from Rs 577 crore reported in a year ago period, driven by more than 20 growth in the CRO division and the Biopharma division at 13-16 percent Y-o-Y.

Biocon Q1 net may rise 8.5% at Rs 85.5 cr: Motilal Oswal

Motilal Oswal expects Biocon to report a 55.3 percent degrowth quarter-on-quarter (growth of 8.5 percent year-on-year) in net profit at Rs 85.5 crore.

Biocon Q4: Analysts expect 9% drop in PAT to Rs 89.4cr

Pharmaceutical firm Biocon is set to declare its fourth quarter FY13 numbers on Thursday. Analysts on an average expect the company's profit after tax to fall by 9 percent year-on-year to Rs 89.4 crore due to lower operational performance, according to CNBC-TV18 poll.

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

Biocon Q3: Analysts expect PAT growing 6% to Rs 90 cr

Healthcare firm Biocon is set to declare its third quarter results on Thursday. Analysts on an average expect profit after tax of the company to grow by 6 percent year-on-year to Rs 89.6 crore in the quarter.

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

Looking at insulin biz to drive growth ahead: Biocon

Kiran Mazumdar Shaw, CMD of Biocon said their branded formulation business has grown 45 percent and excluding it the bio pharma business has seen 20 percent growth year-on-year. She also feels the business is gaining traction in emerging markets and the US.

Biocon Q2: Analysts expect PAT flat at Rs 85.7 cr

Pharmaceutical company Biocon's consolidated profit after tax is expected to be flat at Rs 85.7 crore in the second quarter of FY13 as against Rs 86.3 crore in a year ago period due to higher depreciation and tax rate.

Biocon Q1 PAT seen up 25% to Rs 88 cr

Drug maker Biocon will report its first quarter numbers of FY13 today. Analysts on an average expect the profit after tax to grow by 25% to Rs 88 crore from Rs 70 crore year-on-year.

Biocon Q4 EBITDA likely to go up 11% to Rs 143.4 cr

Pharmaceutical firm Biocon is expected to report a growth of 2% quarter-on-quarter in its profit after tax of Rs 86.2 crore for the fourth quarter of FY12, according to CNBC-TV18 poll. The company had reported PAT of Rs 84.8 crore in the previous quarter.

Biocon Q4 PAT seen up 2% QoQ at Rs 86.2 cr

Pharmaceutical firm Biocon is expected to report a growth of 2% quarter-on-quarter in its profit after tax of Rs 86.2 crore for the fourth quarter of FY12, according to CNBC-TV18 poll. The company had reported PAT of Rs 84.8 crore in the previous quarter.

Biocon sees larger licensing income from pharma

Biocon, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.

Biocon Q3 PAT seen up 10% to Rs 94 cr QoQ

Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.

Biocon aims to maintain 35-40% growth in branded healthcare

Bicon aims to maintain its 35-40% growth in its two top business verticals - research services and branded formulations, said CMD Kiran Mazumdar-Shaw in an exclusive interview to CNBC-TV18.

Biocon Q2 PAT seen up 18% at Rs 82 cr QoQ

Pharmaceutical firm Biocon is expected to report a growth of 18% quarter-on-quarter in profit after tax of Rs 82 crore in the quarter ended September 2011. The company had reported net profit of Rs 70 crore in the previous quarter.

Biocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis.

Biocon Q1 PAT seen up 24% to Rs 95 cr

Biocon is expected to report 24% jump in its first quarter FY12 profit after tax to Rs 95 crore against Rs 76.7 crore in the year ago period.

To improve market share, position in Germany: Dr Reddy's

GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.

Biocon Q4 net up 25%, divests stake in German unit

India's largest listed biotechnology firm Biocon said on Thursday it would divest its stake in German unit AxiCorp, after roughly meeting estimates with a 25% rise in the fourth-quarter net profit.

Biocon Mar qtr PAT seen up at Rs 88.3 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Biocon March quarter sales are expected to go up by 6.5% at Rs 699.4 crore, year-on-year, (YoY) basis.

Biocon delivers stellar Q3 nos, plans to diversify biz

Biocon has had a spectacular third quarter. Its consolidated revenues for the period have surged 15%, and this has helped net profit jump 25%. CNBC-TV18's Vineetha Athrey finds out what Biocon's doing right, and what lies ahead.

Biocon Q3 profit after tax seen up 15% to Rs 93 cr

Indian biotechnology firm Biocon is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected go up by 15% to Rs 93 crore in Q3FY11 as against Rs 80.9 crore in same period of previous year.